Benefits
Short term weight loss, small in size and uncertain in relevance
What the cited evidence actually shows: a 2011 systematic review and meta-analysis of randomized trials of Garcinia extracts and HCA concluded that they can cause short term weight loss, that the magnitude of the effect is small, and that the clinical relevance is uncertain. The claim that 90 percent of a GarCitrin group and none of the placebo group lost more than 5 percent of body weight is not published in any reference on this page, so it cannot be checked. A 90 percent versus zero percent response rate is far outside what randomized trials of Garcinia and HCA have reported, and the study behind it tested LeanGard, a proprietary blend that contains GarCitrin along with other ingredients, not GarCitrin on its own.
Body composition claims that rest on an uncited study
In a double-blind study comparing GarCitrin (500 mg HCA calcium salt + 25 mg garcinol) vs HCA alone in overweight women (BMI >25), the GarCitrin group showed statistically significant decreases in body weight and fat content, and significant increases in lean body mass and total body water vs both baseline and the HCA-alone group. That head to head study is not among the four references on this page, so its methods and statistics cannot be checked. Treat it as an uncited supplier report. None of the four references tested GarCitrin or compared it with plain HCA.
Reduced appetite levels
The same trial documented significantly reduced perceived appetite in the GarCitrin group vs both baseline and the HCA-only group. That trial is also uncited. The only appetite study among the references ran for 2 weeks, tested HCA alone and HCA with medium chain triglycerides rather than GarCitrin, and 2 weeks is too short to say anything about lasting weight management.
Garcinol enhances HCA bioavailability
Garcinia indica garcinol enhances the biological action of HCA — addressing the long-standing problem of poor HCA bioavailability in the cytosol of target cells (one of the primary reasons earlier HCA clinical studies showed mixed results). No reference on this page measured HCA levels in blood or tissue, and none compared GarCitrin with HCA alone, so the bioavailability advantage is a proposed mechanism and a supplier claim rather than a published finding.
Antioxidant activity contribution
Garcinol is a polyisoprenylated benzophenone that scavenges superoxide in laboratory assays, where emulsified garcinol performed similarly to DL-alpha-tocopherol (vitamin E). That is test tube chemistry. None of the references measured antioxidant status in people, and antioxidant activity in a dish does not predict any effect in the body.
Body mass index improvement
The BMI reduction attributed to GarCitrin comes from the same uncited 46 person study and cannot be verified against any reference listed here. In the pooled randomized data for Garcinia and HCA, weight changes were small and the meta-analysis authors called their clinical relevance uncertain.
ATP citrate lyase inhibition mechanism
(-) HCA competes with citrate for the enzymatic activity of ATP citrate lyase in the cytoplasm — a key enzyme in lipogenesis (fat synthesis). Inhibition reduces acetyl-CoA formation from citrate, decreasing fatty acid and cholesterol synthesis. The often quoted figure that HCA binds citrate lyase about 100 times more tightly than citrate is not cited on this page. It is an enzyme binding measurement, and blocking an enzyme is not the same as losing weight, so this card describes a proposed mechanism rather than a measured result in people.
Indian culinary traditional use
Garcinia cambogia (Malabar tamarind, brindall berry) and Garcinia indica (kokum) have history of traditional culinary use in India — kokum is a common souring agent in Western Indian cuisine. Eating the fruit as a souring agent in cooking is not the same as taking a concentrated HCA extract every day, and a history of culinary use does not establish the safety of a concentrated supplement.
Mechanism of action
ATP citrate lyase inhibition (HCA mechanism)
(-) HCA competes with citrate for ATP citrate lyase — the enzyme converting citrate to acetyl-CoA in the cytoplasm. Acetyl-CoA is the major precursor of fatty acids and malonyl-CoA. Inhibiting citrate lyase reduces fatty acid synthesis and lipid accumulation. HCA has 100× greater affinity for citrate lyase than citrate.
Garcinol bioavailability enhancement
Garcinol enhances the biological action of HCA by improving its bioavailability in the cytosol of target cells. No human pharmacokinetic study is cited on this page showing that garcinol raises HCA levels inside cells, so this remains a proposal rather than a demonstrated mechanism. Garcinol's lipophilic nature may support membrane transport of HCA.
Antioxidant superoxide scavenging
Garcinol scavenges superoxide anion similar in potency to DL-alpha-tocopherol (vitamin E). Antioxidant activity may support metabolic health beyond pure weight management — oxidative stress contributes to insulin resistance and metabolic dysfunction. Multi-mechanism approach beyond single-pathway intervention.
Appetite modulation
HCA affects appetite via mechanisms not fully characterized — may involve serotonergic effects (relevant for carbohydrate cravings) plus signaling from satiety pathways. The appetite reduction attributed to GarCitrin comes from an uncited study, and the one cited satiety study lasted 2 weeks and tested HCA rather than GarCitrin.
Lean body mass preservation
The claim that GarCitrin increases lean body mass while reducing fat rests on a single uncited study reported by the ingredient supplier. No trial cited on this page tested GarCitrin, so body recomposition should be read as an unproven proposal rather than a demonstrated effect. Maintaining lean mass supports metabolism and physical function during weight loss.
Clinical trials
Double-blind 12-week clinical study comparing GarCitrin (500 mg calcium salt HCA + 25 mg garcinol) vs HCA alone (500 mg calcium salt HCA only). Uncited. This study is not among the four references on this page and no journal, year or PubMed record is given for it, so its design, statistics and publication status cannot be checked. It is reported by the ingredient supplier.
46 overweight female volunteers (BMI >25). 12-week double-blind intervention.
GarCitrin group: statistically significant decreases in body weight, fat content, and BMI; statistically significant increases in lean body mass and total body water; significantly reduced perceived appetite levels vs both baseline and HCA-only group. Because the report is uncited, none of these figures can be verified, and nothing here establishes a garcinol enhancement effect or an advantage over generic HCA.
12-week randomized placebo-controlled clinical trial of LeanGard (proprietary blend including GarCitrin) at 500 mg/day vs placebo in overweight and obese subjects. Reported as conducted by researchers led by Noor Khan, MD, at Shifaa Hospital in Bangalore, India. The report is not among the references on this page and is not cited to any journal, so it cannot be verified. The product tested was LeanGard, a blend that contains GarCitrin along with other ingredients, so any result belongs to the blend and not to GarCitrin.
50 overweight and obese subjects (26 women, ages 25-55). 12-week intervention.
The reported result, that 90 percent of the LeanGard group and none of the placebo group lost more than 5 percent of body weight, is not published in any reference on this page and cannot be checked. A response rate that large against a zero percent placebo response is far outside what randomized trials of Garcinia and HCA have reported, and the pooled trial data describe small short term weight changes of uncertain clinical relevance. The 5% weight loss threshold is clinically meaningful — associated with metabolic and cardiovascular health improvements. Even if the numbers were published, they would belong to the LeanGard blend and could not be attributed to GarCitrin.
This entry is not a study and should not be counted as clinical evidence. It records only that Sabinsa holds US Patent #7,063,861 covering a composition of HCA with garcinol. A patent is an intellectual property grant. Patent examiners judge novelty and non obviousness, not whether a product works or is safe, and no human data are required to obtain one.
No participants. There is no study here, only a patent grant.
No health outcome was measured, because a patent is not a study. A patent grant cannot support a synergy claim, a body recomposition claim, or any advantage over generic HCA.